

WHO Drug Information

Contents

General Policy Issues

- WHO Model List of Essential Drugs celebrates its twentieth anniversary 231
- The continuing need for rational selection and use of drugs 232

Current Topics

- Prevention of mother-to-child transmission of HIV in developing countries 234
- Improving patient compliance with antimalarials 236

Reports on Individual Drugs

- Fenfluramine and dexfenfluramine recalled worldwide 240
- Reduction in use of antimicrobials decreases resistance 241
- Inhaled corticosteroids and the risk of cataract 243

General Information

- Transmissible spongiform encephalopathies and medical products 244
- Data mining and drug safety 247
- Developments in monitoring of antimicrobial resistance 248

Regulatory Matters

- Unapproved test kits on Internet 250
- Alendronic acid and oesophagitis 250
- Pethidine-associated convulsions 250
- Strict control for zopiklon and zolpidem 250
- Drug-induced gynecomastia 250

- Paracetamol and acetylsalicylic acid: restrictions on pack size 250
- First fixed-combination drug for HIV 251
- Clobetasol found in over-the-counter topical product 251
- Thalidomide recommended for approval 251
- First COMT inhibitor for Parkinson disease 251
- Phenolphthalein laxatives and cancer risk 251
- Warning of herbal products sold as alternatives to abuse drugs 252
- Dietary supplement products containing digitalis 252
- Medication errors involving HIV drugs 252

Essential Drugs

WHO Model Formulary

Antibacterials

- Antileprosy drugs 253
- Clofazimine 255
- Dapsone 255
- Rifampicin 256
- Minocycline 256
- Ofloxacin 256
- Antituberculosis drugs 257
- Isoniazid 258
- Rifampicin 260
- Rifampicin/isoniazid 260
- Pyrazinamide 261
- Streptomycin 261
- Ethambutol 261
- Thioacetazone/isoniazid 262
- Ethambutol/isoniazid 262
- Rifampicin/isoniazid/pyrazinamide 263
- BCG vaccine (dried) 263
- Tuberculin (purified protein derivative) 263

Proposed International Nonproprietary Names: List 78